Moderna Stock Surges Following Breakthrough in Personalized mRNA Cancer Vaccine Trial

Cambridge, Saturday, 22 August 2026.
Moderna and Merck achieved a major milestone in August 2026 as their personalized mRNA melanoma vaccine met primary Phase 3 endpoints, sending Moderna’s stock soaring.